Literature DB >> 17186064

Molecular Mechanisms for Altered Glucose Homeostasis in HIV Infection.

Paul W Hruz1.   

Abstract

A complete understanding of the molecular mechanisms leading to HIV-associated insulin resistance remains elusive. Complex interrelationships between genetic predisposition, disease-related body changes and multidrug therapy all contribute to alterations in glucose homeostasis. These abnormalities can be differentiated between acute and reversible changes directly induced by HAART medications and more chronic and less reversible changes due to the development of lipodystrophy and hyperlipidemia. Implicated pathways include changes in adipokine secretion, insulin signaling, lipid homeostasis and disease-related increases in inflammatory mediators. The insulin responsive facilitative glucose transporter GLUT4 is the first molecule to have been identified as a direct target of HIV protease inhibitors. Efforts to elucidate the mechanisms directly responsible for the evolution of insulin resistance during HIV infection and therapy will be greatly assisted by the further identification and characterization of direct molecular targets amenable to pharmacologic therapy and/or the development of newer antiretroviral agents that do not adversely affect these target proteins.

Entities:  

Year:  2006        PMID: 17186064      PMCID: PMC1716153          DOI: 10.3844/ajidsp.2006.187.192

Source DB:  PubMed          Journal:  Am J Infect Dis        ISSN: 1553-6203


  44 in total

1.  Hyperlipidemia and insulin resistance are induced by protease inhibitors independent of changes in body composition in patients with HIV infection.

Authors:  K Mulligan; C Grunfeld; V W Tai; H Algren; M Pang; D N Chernoff; J C Lo; M Schambelan
Journal:  J Acquir Immune Defic Syndr       Date:  2000-01-01       Impact factor: 3.731

2.  Adiponectin and leptin levels in HIV-infected subjects with insulin resistance and body fat redistribution.

Authors:  Dennis C Mynarcik; Terry Combs; Margaret A McNurlan; Philipp E Scherer; Eugene Komaroff; Marie C Gelato
Journal:  J Acquir Immune Defic Syndr       Date:  2002-12-15       Impact factor: 3.731

3.  The mechanism of insulin resistance caused by HIV protease inhibitor therapy.

Authors:  H Murata; P W Hruz; M Mueckler
Journal:  J Biol Chem       Date:  2000-07-07       Impact factor: 5.157

4.  Indinavir induces acute and reversible peripheral insulin resistance in rats.

Authors:  Paul W Hruz; Haruhiko Murata; Haijun Qiu; Mike Mueckler
Journal:  Diabetes       Date:  2002-04       Impact factor: 9.461

5.  Prospective, intensive study of metabolic changes associated with 48 weeks of amprenavir-based antiretroviral therapy.

Authors:  Michael P Dubé; Dajun Qian; Hannah Edmondson-Melançon; Fred R Sattler; Diane Goodwin; Carmen Martinez; Vanessa Williams; Debra Johnson; Thomas A Buchanan
Journal:  Clin Infect Dis       Date:  2002-07-23       Impact factor: 9.079

Review 6.  Inflammatory pathways and insulin action.

Authors:  G S Hotamisligil
Journal:  Int J Obes Relat Metab Disord       Date:  2003-12

7.  HIV protease inhibitors acutely impair glucose-stimulated insulin release.

Authors:  Joseph C Koster; Maria S Remedi; Haijun Qiu; Colin G Nichols; Paul W Hruz
Journal:  Diabetes       Date:  2003-07       Impact factor: 9.461

Review 8.  Pathogenesis of type 2 diabetes mellitus.

Authors:  Ralph A DeFronzo
Journal:  Med Clin North Am       Date:  2004-07       Impact factor: 5.456

Review 9.  The inherited basis of diabetes mellitus: implications for the genetic analysis of complex traits.

Authors:  Jose C Florez; Joel Hirschhorn; David Altshuler
Journal:  Annu Rev Genomics Hum Genet       Date:  2003       Impact factor: 8.929

10.  Leptin replacement therapy but not dietary polyunsaturated fatty acid alleviates HIV protease inhibitor-induced dyslipidemia and lipodystrophy in mice.

Authors:  Tara M Riddle; Carl J Fichtenbaum; David Y Hui
Journal:  J Acquir Immune Defic Syndr       Date:  2003-08-15       Impact factor: 3.731

View more
  13 in total

1.  HIV-protease inhibitors suppress skeletal muscle fatty acid oxidation by reducing CD36 and CPT1 fatty acid transporters.

Authors:  Scott R Richmond; Michael J Carper; Xiaoyong Lei; Sheng Zhang; Kevin E Yarasheski; Sasanka Ramanadham
Journal:  Biochim Biophys Acta       Date:  2010-02-01

2.  Differential subcutaneous adipose tissue gene expression patterns in a randomized clinical trial of efavirenz or lopinavir-ritonavir in antiretroviral-naive patients.

Authors:  L Egaña-Gorroño; E Martínez; P Domingo; M Loncà; T Escribà; J Fontdevila; F Vidal; E Negredo; J M Gatell; M Arnedo
Journal:  Antimicrob Agents Chemother       Date:  2014-08-25       Impact factor: 5.191

3.  Hormonal and Metabolic Disorders of Human Immunodeficiency Virus Infection and Substance Abuse.

Authors:  Jag H Khalsa; Frank Vocci; Adrian Dobs
Journal:  Am J Infect Dis       Date:  2006

4.  Factors associated with insulin resistance among children and adolescents perinatally infected with HIV-1 in the pediatric HIV/AIDS cohort study.

Authors:  Mitchell E Geffner; Kunjal Patel; Tracie L Miller; Rohan Hazra; Margarita Silio; Russell B Van Dyke; William Borkowsky; Carol Worrell; Linda A DiMeglio; Denise L Jacobson
Journal:  Horm Res Paediatr       Date:  2011-10-26       Impact factor: 2.852

5.  Short communication: The relationship between mitochondrial dysfunction and insulin resistance in HIV-infected children receiving antiretroviral therapy.

Authors:  Tanvi S Sharma; Denise L Jacobson; Lynn Anderson; Mariana Gerschenson; Russell B Van Dyke; Elizabeth J McFarland; Tracie L Miller
Journal:  AIDS Res Hum Retroviruses       Date:  2013-09       Impact factor: 2.205

6.  Naringin prevents HIV-1 protease inhibitors-induced metabolic complications in vivo.

Authors:  Sanelisiwe Nzuza; Sindiswa Zondi; Peter M O Owira
Journal:  PLoS One       Date:  2017-11-09       Impact factor: 3.240

7.  Influence of non-nucleoside reverse transcriptase inhibitors (efavirenz and nevirapine) on the pharmacodynamic activity of gliclazide in animal models.

Authors:  Sk Mastan; K Eswar Kumar
Journal:  Diabetol Metab Syndr       Date:  2009-10-09       Impact factor: 3.320

8.  Pharmacokinetic and metabolic effects of American ginseng (Panax quinquefolius) in healthy volunteers receiving the HIV protease inhibitor indinavir.

Authors:  Adriana S A Andrade; Craig Hendrix; Teresa L Parsons; Benjamin Caballero; Chun-Su Yuan; Charles W Flexner; Adrian S Dobs; Todd T Brown
Journal:  BMC Complement Altern Med       Date:  2008-08-19       Impact factor: 3.659

9.  Effect of antiretroviral drugs on the pharmacodynamics of gliclazide with respect to glucose-insulin homeostasis in animal models.

Authors:  S K Mastan; K Eswar Kumar
Journal:  J Exp Pharmacol       Date:  2009-12-23

10.  Risk Factors for Incident Diabetes in a Cohort Taking First-Line Nonnucleoside Reverse Transcriptase Inhibitor-Based Antiretroviral Therapy.

Authors:  Sumanth Karamchand; Rory Leisegang; Michael Schomaker; Gary Maartens; Lourens Walters; Michael Hislop; Joel A Dave; Naomi S Levitt; Karen Cohen
Journal:  Medicine (Baltimore)       Date:  2016-03       Impact factor: 1.889

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.